Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsStridespharmascience

    Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More

    Jump to

    • Bull's Eye: Buy Arvind, Castrol, sell OBC, Shriram Trans

      Manav Chopra of Networth Stock Broking suggests buying Castrol India with a target of Rs 490.

    • Go long in Strides Arcolab: Ashish Chaturmohta

      Ashish Chaturmohta of Fortune Group is of the view that one cango long in Strides Arcolab as the stock may test Rs 1,360-1,370 in next two to three weeks.

    • Bull's Eye: Buy Ashoka Bulidcon, Dish TV, Arvind, Gati

      Krish Subramanyam of Altamount Capital advises buying Orchid Chemicals with a target of Rs 67.

    • Strides Arcolab may rise by Rs 140-150, says Amit Gupta

      According to Amit Gupta of ICICIdirect, Strides Arcolab may rise by Rs 140-150 in couple of series.

    • Buy Voltas, RComm, OBC, Strides Arcolab: Vishal Malkan

      Vishal Malkan of malkansview.com recommends buying Strides Arcolab with a target of Rs 1250 and Oriental Bank of Commerce with a target of Rs 189.

    • Bull's Eye: Buy Voltas, Rel Comm, OBC, sell Oil India

      According to Shahina Mukadam, Market Expert, one may buy Sun Pharma Advanced Research Company (SPARC) with a target of Rs 440.

    • Buy Coal India, LIC Housing, Strides Arcolab: Sukhani

      Sudarshan Sukhani of s2analytics.com recommends buying Coal India, LIC Housing Finance and Strides Arcolab.

    • Strides Arcolab can move to Rs 1215: Rajat Bose

      According to Rajat Bose of rajatkbose.com, Strides Arcolab has some headroom left and it can move to Rs 1215.

    • Buy Strides Arcolab on dips: Hemen Kapadia

      Hemen Kapadia of KR Choksey Securities is of the view that one may buy Strides Arcolab on dips.

    • Your stocks: Top chart picks by market experts

      Watch the interview of Hemen Kapadia of KR Choksey Securities who shared his readings and outlook on specific stocks and sector & Feroze Azeez of Anand Rathi Financial Svcs answered few personal finance queries.

    • Strides Arcolab may hit Rs 1220: Ashish Chaturmohta

      Ashish Chaturmohta of Fortune Group is of the view that Strides Arcolab may hit Rs 1220.

    • Prefer Sun Pharmaceutical Industries: Deepak Shenoy

      Deepak Shenoy of capitalmind.in is of the view that one can purchase Sun Pharmaceutical Industries at the current level.

    • Buy BPCL, Adani Enterprises, Strides Arcolab: Hathiramani

      Manish Hathiramani of Deen Dayal Investments recommends buying Bharat Petroleum Corporation, Adani Enterprises and Strides Arcolab.

    • Strides Arcolab may test Rs 1280, says Manas Jaiswal

      Manas Jaiswal of manasjaiswal.com is of the view that Strides Arcolab may test Rs 1280.

    • Above Rs 1250, Strides Arcolab may hit Rs 1285: Chavan

      According to Sameet Chavan of Angel Broking, Strides Arcolab may test Rs 1285-1290 if it moves above Rs 1250.

    • Modi@365: Best & worst performing stocks

      CNBC-TV18‘s Varinder Bansal gives a check on the best & worst performing stocks in this last one year of Modi government.

    • Strides Arcolab may head higher: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that Strides Arcolab may head higher.

    • Look at Strides Arcolab: Dipan Mehta

      Dipan Mehta, Member at BSE & NSE is of the view that one may look at Strides Arcolab.

    • Strides Arcolab may hit Rs 1200: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that Strides Arcolab may hit Rs 1200.

    • Hold Lupin, prefer Cadila, Aurobindo Pharma: Anand Tandon

      Market Expert, Anand Tandon is of the view that one may hold Lupin with long term view.

    • Strides Arcolab may test Rs 1135-1140: Hemant Thukral

      According to Hemant Thukral of Aditya Birla Money, Strides Arcolab may touch Rs 1135-1140.

    • Top buzzing midcap stocks to trade on May 15

      Here are a few top buzzing midcap stocks picked by CNBC-TV18's analysts in trade today. We have Strides Arcolab, Tata Steel, Jubilant Foodworks, Pc Jeweller, Subex, Bank of Maharashtra, Amtek Auto, Kokuyo Camlin & Nectar Life.

    • Sell Divis Laboratories, Strides Arcolab: Manoj Murlidharan

      Manoj Murlidharan of Religare Securities recommends selling Divis Laboratories and Strides Arcolab.

    • Prefer Infosys, Tech Mahindra, HPCL, Sun Pharma: Damania

      Anish Damania, Head-Institutional Equities at IDFC Securities is of the view that one may prefer Infosys, Tech Mahindra, HPCL, IOC, Sun Pharma, Cipla and Strides Arcolab.

    • Prefer Strides Arcolab, Sun Pharma: Deepak Shenoy

      Deepak Shenoy of Capital Mind is of the view that one may prefer Strides Arcolab and Sun Pharma.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347